Yesterday, Dec. 23, 2015, 71 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $6,987,960.00.

Highlighted Stocks Traded by Insiders:

Bovie Medical (BVX) - FREE Research Report

Citronowicz Moshe, who is Sr. V.P. of Operations at Bovie Medical, bought 20,000 shares at $1.84 on Dec. 23, 2015. Following this transaction, the Sr. V.P. of Operations owned 426,504 shares meaning that the stake was boosted by 4.92% with the 20,000-share transaction.

Gershon Robert, who is Chief Executive Officer at Bovie Medical, bought 10,000 shares at $1.82 on Dec. 23, 2015. Following this transaction, the Chief Executive Officer owned 30,000 shares meaning that the stake was boosted by 50% with the 10,000-share transaction.

McCarthy John J. III, who is Chief Commercialization Office at Bovie Medical, bought 25,000 shares at $1.98 on Dec. 23, 2015. Following this transaction, the Chief Commercialization Office owned 25,000 shares meaning that the stake was boosted by 100% with the 25,000-share transaction.

The shares most recently traded at $1.94, down $0.04, or 1.91% since the insider transaction.

The average volume for Bovie Medical has been 74,200 shares per day over the past 30 days. Bovie Medical has a market cap of $53.0 million and is part of the health care sector and health services industry. Shares are down 45.92% year-to-date as of the close of trading on Wednesday.

Bovie Medical Corporation engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used in doctors' offices, surgery centers, and hospitals worldwide. Currently, there are 2 analysts who rate Bovie Medical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BVX - FREE

TheStreet Quant Ratings rates Bovie Medical as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Bovie Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Middlesex Water (MSEX) - FREE Research Report

Sohler Bernadette M, who is VP-Corporate Affairs at Middlesex Water, sold 900 shares at $27.55 on Dec. 23, 2015. Following this transaction, the VP-Corporate Affairs owned 900 shares meaning that the stake was reduced by 50% with the 900-share transaction.

The shares most recently traded at $27.27, down $0.28, or 1.03% since the insider transaction. Historical insider transactions for Middlesex Water go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 800
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 800
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 800

The average volume for Middlesex Water has been 38,300 shares per day over the past 30 days. Middlesex Water has a market cap of $445.2 million and is part of the utilities sector and utilities industry. Shares are up 19.08% year-to-date as of the close of trading on Wednesday.

Middlesex Water Company, through its subsidiaries, provides regulated and unregulated water, and wastewater utility services. The company operates in two segments, Regulated and Non-Regulated. The stock currently has a dividend yield of 2.9%. The company has a P/E ratio of 23.3. Currently, there is 1 analyst who rates Middlesex Water a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MSEX - FREE

TheStreet Quant Ratings rates Middlesex Water as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Middlesex Water Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Triangle Petroleum (TPLM) - FREE Research Report

Samuels Jonathan Ryan, who is President and CEO at Triangle Petroleum, sold 12,000 shares at $0.81 on Dec. 23, 2015. Following this transaction, the President and CEO owned 455,482 shares meaning that the stake was reduced by 2.57% with the 12,000-share transaction.

The shares most recently traded at $0.79, down $0.02, or 2.53% since the insider transaction. Historical insider transactions for Triangle Petroleum go as follows:

  • 4-Week # shares bought: 120,000
  • 4-Week # shares sold: 20,000
  • 12-Week # shares bought: 120,000
  • 12-Week # shares sold: 20,000
  • 24-Week # shares bought: 173,955
  • 24-Week # shares sold: 20,000

The average volume for Triangle Petroleum has been 965,800 shares per day over the past 30 days. Triangle Petroleum has a market cap of $48.0 million and is part of the basic materials sector and energy industry. Shares are down 83.26% year-to-date as of the close of trading on Wednesday.

Triangle Petroleum Corporation, an independent energy company, explores for, develops, and produces oil and natural gas resources primarily in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana. Currently, there is 1 analyst who rates Triangle Petroleum a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TPLM - FREE

TheStreet Quant Ratings rates Triangle Petroleum as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full Triangle Petroleum Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.